Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. Cardiovascular Revascularization Medicine 2023, 53: s126. DOI: 10.1016/j.carrev.2023.05.290.Peer-Reviewed Original ResearchCRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. CRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. JACC Cardiovascular Interventions 2023, 16: s107. DOI: 10.1016/j.jcin.2023.01.337.Peer-Reviewed Original Research